基线及纵向血清UMOD与肾衰竭及死亡风险的关联:AASK试验结果
AASK试验前瞻性队列纳入500例有基线血清UMOD的非洲裔美国CKD合并高血压患者,中位随访8.5年发生161例KFRT。校正基线因素后,基线UMOD降低50%与KFRT风险升高35%独立相关(aHR 1.35),UMOD年变化每低1个SD与KFRT风险升高67%相关(aHR 1.67);UMOD与死亡无关联。
要点
- 基线血清UMOD较低与后续KFRT风险升高独立相关(aHR 1.35)。
- UMOD年变化每低1个SD,KFRT风险升高67%(aHR 1.67)。
- 基线及纵向UMOD变化均与死亡风险无显著关联。
核心结论
- 在非洲裔美国CKD合并高血压成人中,基线UMOD较低及随访中UMOD下降更陡均与后续KFRT风险升高相关,但与死亡无关联。
研究设计与样本
- AASK试验的前瞻性队列,纳入有0、12、24个月储存血清样本的参与者500例,平均年龄54岁,女性37%。
主要发现
- 中位随访8.5年发生161例KFRT事件。
- 校正人口学、临床因素、GFR、对数尿蛋白肌酐比及随机治疗组后,基线UMOD降低50%与KFRT风险升高35%独立相关(aHR 1.35;95%CI 1.07-1.70)。
- UMOD年变化每低1个SD与KFRT风险升高67%相关(aHR 1.67;95%CI 1.41-1.99)。
- 基线UMOD及UMOD变化与死亡风险无显著关联。
- UMOD下降在美托洛尔组较雷米普利组更陡(P<0.001),强化降压组较标准降压组更陡(P=0.002)。
关键数值与推荐
- 基线UMOD降低50%对应的KFRT风险aHR为1.35(95%CI 1.07-1.70)。
- UMOD年变化每低1个SD对应的KFRT风险aHR为1.67(95%CI 1.41-1.99)。
- UMOD年变化在美托洛尔组较雷米普利组更陡(P<0.001)。
- UMOD年变化在强化降压组较标准降压组更陡(P=0.002)。
临床怎么用
- 血清UMOD可作为肾病进展风险的候选生物标志物,但本研究未提供临床决策阈值或干预方案。
局限性
- 样本量小。
- 普遍性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Uromodulin (UMOD) is the most abundant protein found in urine and has emerged as a promising biomarker of tubule health. Circulating UMOD is also detectable, but at lower levels. We evaluated whether serum UMOD levels were associated with the risks of incident kidney failure with replacement therapy (KFRT) and mortality. STUDY DESIGN: Prospective cohort. SETTING & PARTICIPANTS: Participants in AASK (the African American Study of Kidney Disease and Hypertension) with available stored serum samples from the 0-, 12-, and 24-month visits for biomarker measurement. PREDICTORS: Baseline log-transformed UMOD and change in UMOD over 2 years. OUTCOMES: KFRT and mortality. ANALYTICAL APPROACH: Cox proportional hazards and mixed-effects models. RESULTS: Among 500 participants with baseline serum UMOD levels (mean age, 54y; 37% female), 161 KFRT events occurred during a median of 8.5 years. After adjusting for baseline demographic factors, clinical factors, glomerular filtration rate, log-transformed urine protein-creatinine ratio, and randomized treatment groups, a 50% lower baseline UMOD level was independently associated with a 35% higher risk of KFRT (adjusted HR, 1.35; 95% CI, 1.07-1.70). For annual UMOD change, each 1-standard deviation lower change was associated with a 67% higher risk of KFRT (adjusted HR, 1.67; 95% CI, 1.41-1.99). Baseline UMOD and UMOD change were not associated with mortality. UMOD levels declined more steeply for metoprolol versus ramipril (P<0.001) as well as for intensive versus standard blood pressure goals (P = 0.002). LIMITATIONS: Small sample size and limited generalizability. CONCLUSIONS: Lower UMOD levels at baseline and steeper declines in UMOD over time were associated with a higher risk of subsequent KFRT in a cohort of African American adults with chronic kidney disease and hypertension. PLAIN-LANGUAGE SUMMARY: Prior studies of uromodulin (UMOD), the most abundant protein in urine, and kidney disease have focused primarily on urinary UMOD levels. The present study evaluated associations of serum UMOD levels with the risks of kidney failure with replacement therapy (KFRT) and mortality in a cohort of African American adults with hypertension and chronic kidney disease. It found that participants with lower levels of UMOD at baseline were more likely to experience KFRT even after accounting for baseline kidney measures. Similarly, participants who experienced steeper annual declines in UMOD also had a heightened risk of kidney failure. Neither baseline nor annual change in UMOD was associated with mortality. Serum UMOD is a promising biomarker of kidney health.
引用
- Chen TK, Estrella MM, Appel LJ, et al. Associations of Baseline and Longitudinal Serum Uromodulin With Kidney Failure and Mortality: Results From the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2023. PMID: 37690632. doi:10.1053/j.ajkd.2023.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。